Presentations by Program

Search by Program

The Antibacterial Activity of Sulbactam and the Novel β–lactamase Inhibitor ETX2514 Combined with Imipenem or Meropenem Against Recent Clinical Isolates of Acinetobacter baumannii and Pseudomonas aeruginosa, ASM Microbe, June 2017

Sarah McLeod, ASM Microbe 2017

The Antibacterial Activity of Cefpodoxime and the Novel β–lactamase Inhibitor ETX1317 Against Recent Clinical Isolates of β–lactamase-producing Enterobacteriaceae, ASM Microbe, June 2017

Sarah McLeod, ASM Microbe 2017

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae, ASM Microbe, June 2017

Thomas Durand-Reville, ASM Microbe 2017

Reversibility of β–lactamase inhibition by the broad-spectrum diazabicyclooctenone serine β–lactamase inhibitor ETX2514, ASM Microbe, June 2017

Adam Shapiro, ASM Microbe 2017

ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens, ECCMID, April 2017

Ruben Tommasi, ECCMID 2017

Discovery of ETX2514, a novel, rationally designed inhibitor of Class A, C and D β–lactamases, for the treatment of Gram-negative infections

Thomas Durand-Reville, ACS 2017

ETX2514 restoration of sulbactam activity against multidrug resistant Acinetobacter baumannii correlates with β-lactamase inhibition in vitro and in vivo,

Alita Miller, ECCMID 2017

Pathogen-directed strategies at Entasis Therapeutics

Alita Miller, SDRI 2017

Antibiotic Resistance: A real and present danger in our hospitals

Ruben Tommasi, Gordon Research Conference 2017

Improving our understanding of porin permeability in Gram-negative bacteria

Ruben Tommasi, PEW-NIAID Workshop 2017